World

RNA for Moderna’s omicron booster manufactured by CIA-linked company

Last week, the United Kingdom became the first country to approve Moderna’s reformulated version of its COVID-19 vaccine, which claims to provide protection against both the original form of the virus and the significantly less lethal but more transmissible Omicron variant.

The product was approved by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) with the support of the UK government’s Commission on Human Medicines. Described by UK officials as a “sharpened tool” in the nation’s continued vaccination campaign, the reformulated vaccine combines the previously approved COVID-19 vaccine with a “vaccine candidate” targeting the Omicron variant BA.1.

That vaccine candidate has never been previously approved and has not been the subject of independent study. The MHRA approved the vaccine based on a single, incomplete human trial currently being conducted by Moderna. The company promoted incomplete data from that trial in company press releases in June and July. The study has yet to be published in a medical journal or peer reviewed.

No concerns have been raised by any regulatory agency, including the MHRA, regarding Moderna’s past history of engaging in suspect and likely illegal activity in past product trials, including for its original COVID-19 vaccine. For this new vaccine, including the newly formulated genetic material meant to provide protection against the Omicron variant, is being manufactured, not by Moderna, but by a relatively new company that has received hardly any media attention, despite its obvious links to US intelligence.

The company called, National Resilience was founded in November 2020, and describes itself as “a manufacturing and technology company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption.

In April 2021, National Resilience acquired Ology Bioservices Inc., which had received a $37 million contract from the US military the previous November to develop an advanced anti-COVID-19 monoclonal antibody treatment.

Related posts

Putin: Russia will not export oil subject to Western cap

Loveworld

Worldview: Yvonne Katsande in conversation with Ilya Rogachev on the Russia-Ukraine war

Loveworld

Economy in Germany unexpectedly shrinks in Q4

Loveworld

Leave a Comment